O	0	6	Intent
O	6	7	-
O	7	9	to
O	9	10	-
O	10	15	treat
O	16	24	analysis
O	25	27	of
O	28	31	the
O	32	39	placebo
O	39	40	-
O	40	50	controlled
O	51	56	trial
O	57	59	of
B-intervention	60	69	letrozole
O	70	73	for
O	74	82	extended
O	83	91	adjuvant
O	92	99	therapy
O	100	102	in
B-eligibility	103	108	early
I-eligibility	109	115	breast
I-eligibility	116	122	cancer
O	122	123	:
O	124	128	NCIC
O	129	132	CTG
O	133	135	MA
O	135	136	.
O	136	138	17
O	138	139	.

O	140	142	MA
O	142	143	.
O	143	145	17
O	146	155	evaluated
O	156	165	letrozole
O	166	168	or
B-control	169	176	placebo
O	177	182	after
O	183	184	5
O	185	190	years
O	191	193	of
O	194	203	tamoxifen
O	204	207	and
O	208	214	showed
O	215	226	significant
O	227	238	improvement
O	239	241	in
O	242	249	disease
O	249	250	-
O	250	254	free
O	255	263	survival
O	264	265	(
O	265	268	DFS
O	268	269	)
O	270	273	for
O	274	283	letrozole
O	284	285	[
O	285	291	hazard
O	292	297	ratio
O	298	299	(
O	299	301	HR
O	301	302	)
O	303	304	0
O	304	305	.
O	305	307	57
O	307	308	,
O	309	310	P
O	311	312	=
O	313	314	0
O	314	315	.
O	315	320	00008
O	320	321	]
O	321	322	.

O	323	326	The
O	327	332	trial
O	333	336	was
O	337	346	unblinded
O	347	350	and
O	351	358	placebo
O	359	367	patients
O	368	372	were
O	373	380	offered
O	381	390	letrozole
O	390	391	.

O	392	394	An
O	395	401	intent
O	401	402	-
O	402	404	to
O	404	405	-
O	405	410	treat
O	411	419	analysis
O	420	422	of
O	423	426	all
O	427	435	outcomes
O	435	436	,
O	437	443	before
O	444	447	and
O	448	453	after
O	454	464	unblinding
O	464	465	,
O	466	468	on
O	469	472	the
O	473	478	basis
O	479	481	of
O	482	485	the
O	486	494	original
O	495	508	randomization
O	509	512	was
O	513	520	carried
O	521	524	out
O	524	525	.

O	526	528	In
O	529	532	all
O	532	533	,
B-total-participants	534	538	5187
O	539	547	patients
O	548	552	were
O	553	561	randomly
O	562	571	allocated
O	572	574	to
O	575	578	the
O	579	584	study
O	585	587	at
O	588	596	baseline
O	597	600	and
O	600	601	,
O	602	604	at
O	605	615	unblinding
O	615	616	,
B-control-participants	617	621	1579
O	622	623	(
O	623	625	66
O	625	626	%
O	626	627	)
O	628	630	of
O	631	635	2383
O	636	643	placebo
O	644	652	patients
O	653	661	accepted
O	662	671	letrozole
O	671	672	.

O	673	675	At
O	676	682	median
O	683	689	follow
O	689	690	-
O	690	692	up
O	693	695	of
O	696	698	64
O	699	705	months
O	706	707	(
O	707	712	range
O	713	715	16
O	715	716	-
O	716	718	95
O	718	719	)
O	719	720	,
O	721	724	399
B-outcome	725	736	recurrences
I-outcome	737	739	or
I-outcome	740	753	contralateral
I-outcome	754	760	breast
I-outcome	761	768	cancers
O	769	770	(
O	770	775	CLBCs
O	775	776	)
O	777	778	(
B-iv-bin-abs	778	781	164
O	782	791	letrozole
O	792	795	and
B-cv-bin-abs	796	799	235
O	800	807	placebo
O	807	808	)
O	809	817	occurred
O	817	818	.

B-outcome	819	823	Four
I-outcome	823	824	-
I-outcome	824	828	year
I-outcome	829	832	DFS
O	833	836	was
B-iv-bin-percent	837	839	94
I-iv-bin-percent	839	840	.
I-iv-bin-percent	840	841	3
I-iv-bin-percent	841	842	%
O	843	844	(
O	844	853	letrozole
O	853	854	)
O	855	858	and
B-cv-bin-percent	859	861	91
I-cv-bin-percent	861	862	.
I-cv-bin-percent	862	863	4
I-cv-bin-percent	863	864	%
O	865	866	(
O	866	873	placebo
O	873	874	)
O	875	876	[
O	876	878	HR
O	879	880	0
O	880	881	.
O	881	883	68
O	883	884	,
O	885	887	95
O	887	888	%
O	889	899	confidence
O	900	908	interval
O	909	910	(
O	910	912	CI
O	912	913	)
O	914	915	0
O	915	916	.
O	916	918	55
O	918	919	-
O	919	920	0
O	920	921	.
O	921	923	83
O	923	924	,
O	925	926	P
O	927	928	=
O	929	930	0
O	930	931	.
O	931	935	0001
O	935	936	]
O	937	940	and
O	941	947	showed
O	948	959	superiority
O	960	963	for
O	964	973	letrozole
O	974	976	in
O	977	981	both
O	982	986	node
O	986	987	-
O	987	995	positive
O	996	999	and
O	1000	1001	-
O	1001	1009	negative
O	1010	1018	patients
O	1018	1019	.

O	1020	1033	Corresponding
B-outcome	1034	1035	4
I-outcome	1035	1036	-
I-outcome	1036	1040	year
I-outcome	1041	1048	distant
I-outcome	1049	1052	DFS
O	1053	1056	was
B-iv-bin-percent	1057	1059	96
I-iv-bin-percent	1059	1060	.
I-iv-bin-percent	1060	1061	3
I-iv-bin-percent	1061	1062	%
O	1063	1066	and
B-cv-bin-percent	1067	1069	94
I-cv-bin-percent	1069	1070	.
I-cv-bin-percent	1070	1071	9
I-cv-bin-percent	1071	1072	%
O	1073	1074	(
O	1074	1076	HR
O	1077	1078	0
O	1078	1079	.
O	1079	1081	80
O	1081	1082	,
O	1083	1085	95
O	1085	1086	%
O	1087	1089	CI
O	1090	1091	0
O	1091	1092	.
O	1092	1094	62
O	1094	1095	-
O	1095	1096	1
O	1096	1097	.
O	1097	1099	03
O	1099	1100	,
O	1101	1102	P
O	1103	1104	=
O	1105	1106	0
O	1106	1107	.
O	1107	1110	082
O	1110	1111	)
O	1111	1112	.

B-outcome	1113	1117	Four
I-outcome	1117	1118	-
I-outcome	1118	1122	year
I-outcome	1123	1130	overall
I-outcome	1131	1139	survival
O	1140	1143	was
B-iv-bin-percent	1144	1146	95
I-iv-bin-percent	1146	1147	.
I-iv-bin-percent	1147	1148	1
I-iv-bin-percent	1148	1149	%
O	1150	1153	for
O	1154	1158	both
O	1159	1165	groups
O	1165	1166	.

O	1167	1170	The
B-outcome	1171	1177	annual
I-outcome	1178	1182	rate
I-outcome	1183	1185	of
I-outcome	1186	1190	CLBC
O	1191	1194	was
B-iv-bin-percent	1195	1196	0
I-iv-bin-percent	1196	1197	.
I-iv-bin-percent	1197	1199	28
I-iv-bin-percent	1199	1200	%
O	1201	1204	for
O	1205	1214	letrozole
O	1215	1218	and
B-cv-bin-percent	1219	1220	0
I-cv-bin-percent	1220	1221	.
I-cv-bin-percent	1221	1223	46
I-cv-bin-percent	1223	1224	%
O	1225	1228	for
O	1229	1236	placebo
O	1237	1245	patients
O	1246	1247	(
O	1247	1249	HR
O	1250	1251	0
O	1251	1252	.
O	1252	1254	61
O	1254	1255	,
O	1256	1258	95
O	1258	1259	%
O	1260	1262	CI
O	1263	1264	0
O	1264	1265	.
O	1265	1267	39
O	1267	1268	-
O	1268	1269	0
O	1269	1270	.
O	1270	1272	97
O	1272	1273	,
O	1274	1275	P
O	1276	1277	=
O	1278	1279	0
O	1279	1280	.
O	1280	1283	033
O	1283	1284	)
O	1284	1285	.

O	1286	1294	Patients
O	1295	1305	originally
O	1306	1314	randomly
O	1315	1323	assigned
O	1324	1326	to
O	1327	1334	receive
O	1335	1344	letrozole
O	1345	1351	within
O	1352	1353	3
O	1354	1360	months
O	1361	1363	of
O	1364	1372	stopping
O	1373	1382	tamoxifen
O	1383	1386	did
O	1387	1393	better
O	1394	1398	than
O	1399	1406	placebo
O	1407	1415	patients
O	1416	1418	in
O	1419	1422	DFS
O	1423	1426	and
O	1427	1431	CLBC
O	1431	1432	,
O	1433	1440	despite
O	1441	1443	66
O	1443	1444	%
O	1445	1447	of
O	1448	1455	placebo
O	1456	1464	patients
O	1465	1471	taking
O	1472	1481	letrozole
O	1482	1487	after
O	1488	1498	unblinding
O	1498	1499	.
